JP7573881B2 - 網膜細胞からリポフスチンを除去する活性を有する組成物 - Google Patents

網膜細胞からリポフスチンを除去する活性を有する組成物 Download PDF

Info

Publication number
JP7573881B2
JP7573881B2 JP2021552728A JP2021552728A JP7573881B2 JP 7573881 B2 JP7573881 B2 JP 7573881B2 JP 2021552728 A JP2021552728 A JP 2021552728A JP 2021552728 A JP2021552728 A JP 2021552728A JP 7573881 B2 JP7573881 B2 JP 7573881B2
Authority
JP
Japan
Prior art keywords
cyclodextrin
pharma
composition
βcd
lipofuscin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525007A5 (https=
JP2022525007A (ja
Inventor
マルセロ エム ノチアーリ
エンリケ ロドリゲス ボーラン
Original Assignee
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2022525007A publication Critical patent/JP2022525007A/ja
Publication of JP2022525007A5 publication Critical patent/JP2022525007A5/ja
Application granted granted Critical
Publication of JP7573881B2 publication Critical patent/JP7573881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021552728A 2019-03-05 2020-03-03 網膜細胞からリポフスチンを除去する活性を有する組成物 Active JP7573881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
US62/814,028 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (3)

Publication Number Publication Date
JP2022525007A JP2022525007A (ja) 2022-05-11
JP2022525007A5 JP2022525007A5 (https=) 2023-03-08
JP7573881B2 true JP7573881B2 (ja) 2024-10-28

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552728A Active JP7573881B2 (ja) 2019-03-05 2020-03-03 網膜細胞からリポフスチンを除去する活性を有する組成物

Country Status (16)

Country Link
US (1) US20220118002A1 (https=)
EP (1) EP3934660A4 (https=)
JP (1) JP7573881B2 (https=)
KR (1) KR20210142651A (https=)
CN (1) CN113747902A (https=)
AU (1) AU2020232266A1 (https=)
BR (1) BR112021017529A2 (https=)
CA (1) CA3132466A1 (https=)
CO (1) CO2021012267A2 (https=)
EA (1) EA202192183A1 (https=)
IL (1) IL286002A (https=)
MX (1) MX2021010650A (https=)
PH (1) PH12021552131A1 (https=)
SG (1) SG11202109541YA (https=)
WO (1) WO2020180872A1 (https=)
ZA (1) ZA202106559B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205822A1 (en) * 2021-01-22 2022-07-28 Marcelo M. NOCIARI Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
AU2023420130A1 (en) * 2022-12-30 2025-08-14 Cornell University Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
WO2025147228A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513612A (ja) 2009-12-11 2013-04-22 ニューロン システムズ， インコーポレイテッド 黄斑変性の処置のための組成物および方法
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
WO2018091859A1 (en) 2016-11-18 2018-05-24 Warneford Healthcare Limited Ophthalmic compositions comprising a cyclodextrin as sole active agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513612A (ja) 2009-12-11 2013-04-22 ニューロン システムズ， インコーポレイテッド 黄斑変性の処置のための組成物および方法
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
WO2018091859A1 (en) 2016-11-18 2018-05-24 Warneford Healthcare Limited Ophthalmic compositions comprising a cyclodextrin as sole active agent

Also Published As

Publication number Publication date
EP3934660A4 (en) 2022-11-23
WO2020180872A1 (en) 2020-09-10
CA3132466A1 (en) 2020-09-10
PH12021552131A1 (en) 2022-08-22
KR20210142651A (ko) 2021-11-25
CN113747902A (zh) 2021-12-03
US20220118002A1 (en) 2022-04-21
EP3934660A1 (en) 2022-01-12
EA202192183A1 (ru) 2022-01-14
ZA202106559B (en) 2025-01-29
IL286002A (en) 2021-10-31
JP2022525007A (ja) 2022-05-11
AU2020232266A1 (en) 2021-09-23
SG11202109541YA (en) 2021-09-29
BR112021017529A2 (pt) 2021-11-09
MX2021010650A (es) 2021-12-10
CO2021012267A2 (es) 2021-10-20

Similar Documents

Publication Publication Date Title
US10849922B2 (en) Treatments for retinal disorders
JP7573881B2 (ja) 網膜細胞からリポフスチンを除去する活性を有する組成物
US20240398729A1 (en) Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders
US20240082283A1 (en) Methods of treating diseases
Rani et al. In vitro and in vivo studies reveal the beneficial effects of chlorogenic acid against ER stress mediated ER-phagy and associated apoptosis in the heart of diabetic rat
HK1242998A1 (zh) 治疗法布里病的给药方案
US12157779B2 (en) Cyclodextrin dimers, compositions thereof, and uses thereof
JP2016515600A (ja) エンパグリフロジンの治療的使用
Zhao et al. Trimetazidine inhibits cardiac fibrosis by reducing reactive oxygen species and downregulating connective tissue growth factor in streptozotocin-induced diabetic rats
AU2017257496B2 (en) Prevention of drug-induced atrio-ventricular block
Broeyer et al. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline‐treated breast cancer patients
JP2019529402A (ja) リポタンパク質代謝障害の治療のための化合物
Sobhy et al. Phytosterols disaggregate bovine serum albumin under the glycation conditions through interacting with its glycation sites and altering its secondary structure elements
Toldo et al. Altered oxido-reductive state in the diabetic heart: loss of cardioprotection due to protein disulfide isomerase
KR20210041595A (ko) 커큐미노이드 조성물
CN101072569A (zh) 含有尿苷的组合物及使用其的方法
Li et al. Bioinspired fine-tuning of the mechanical rigidity of SNEDDS for the efficient crossing of multiple gastrointestinal barriers
Tahara et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice
CN104703592A (zh) 治疗轻度和中度阿尔茨海默病的方法
US20240082221A1 (en) Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
US9283243B2 (en) CD36 inhibition to control obesity and insulin sensitivity
Hussein The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure.
Akl et al. Hypothesis Not peer-reviewed version
Green et al. Diagnostic significance of octadeca-9, 11-dienoic acid in cervical neoplasia
KR20230175183A (ko) 화합물을 표적화하는 리소좀-관련 막 단백질 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241008

R150 Certificate of patent or registration of utility model

Ref document number: 7573881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150